HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

La Roche-Posay Relies On Skin-Healing Extract To Treat Eye Wrinkles

This article was originally published in The Rose Sheet

Executive Summary

La Roche-Posay introduces Redermic Eyes, the newest addition to its Redermic line of anti-wrinkle firming care containing Madecassoside, a patented combination known for its skin-healing properties

You may also be interested in...



La Roche-Posay Launches New Offerings At Skin-Care Gaps

L'Oreal brand La Roche-Posay has unveiled a slew of new formulas positioned to address skin-care concerns that are either not effectively or safely treated by other products on the market.

Energizer Grows Personal Care With Acquisition Of Leading Sun-Care Brands

Energizer Holdings will gain Banana Boat and Hawaiian Tropic - the No. 2- and No. 4-selling sun- care brands, respectively - through its $1.9 billion purchase of Playtex Products, the companies announce July 12

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel